New Stock News | Highlight Pharmaceuticals submits application to Hong Kong Exchange for exploring and developing safe and effective treatments for global autoimmune disease patients.

According to the financial news app Zaocaijing, as disclosed by the Hong Kong Stock Exchange on December 4th, Hangzhou Gaoguang Pharmaceutical Co., Ltd. (hereinafter referred to as Gaoguang Pharmaceutical) has submitted its application to the main board of the Hong Kong Stock Exchange, with China International Capital Corporation and CMB International as its joint sponsors. According to the prospectus, Gaoguang Pharmaceutical is committed to exploring and developing safe and effective therapies for global autoimmune/inflammatory disease patients, and has established a unique advantage in the challenging field of neuroinflammation with world-class candidate drugs for the treatment of Alzheimer's and Parkinson's diseases. With end-to-end internal capabilities ranging from target selection, candidate drug discovery to clinical development, the company has built a differentiated asset portfolio covering a variety of autoimmune and neurodegenerative disease indications, including four candidates in clinical stage and multiple candidates in preclinical stage.